Evidence map›Paper›PMID 41450503›Full record

ArticleFrontiers in public health2025

The CATALYTIC tool to assess feasibility of implementing evidence-based interventions for cardiovascular diseases in 46 low- and middle-income countries: survey outcomes and tool reliability testing.

Temitope Ojo, Hanan Yassin, Esther Sowunmi, Tania Hameed, Nessa Ryan, Joyce Gyamfi, Donna Shelley, Olugbenga Ogedegbe, Emmanuel Peprah

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Temitope OjoDivision of Infectious Diseases, School of Medicine at Washington University in St Louis, St. Louis, MO, United States.
Hanan YassinDepartment of Global and Environmental Health, New York University School of Global Public Health, New York, NY, United States.
Esther SowunmiDepartment of Public Health Policy and Management, New York University School of Global Public Health, New York, NY, United States.
Tania HameedDepartment of Global and Environmental Health, New York University School of Global Public Health, New York, NY, United States.
Nessa RyanDepartment of Global and Environmental Health, New York University School of Global Public Health, New York, NY, United States.
Joyce GyamfiDepartment of Global and Environmental Health, New York University School of Global Public Health, New York, NY, United States.
Donna ShelleyDepartment of Public Health Policy and Management, New York University School of Global Public Health, New York, NY, United States.
Olugbenga OgedegbeDepartment of Population Health, NYU Langone Health-NYU Grossman School of Medicine, New York, NY, United States.
Emmanuel PeprahDepartment of Social and Behavioral Sciences, New York University School of Global Public Health, New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Evidence-based interventions (EBI) for cardiovascular disease (CVD) in low- and middle-income countries (LMIC) may face feasibility challenges due to the inadequacy of existing instruments. To address this, researchers developed the Contextual Index of Feasibility on Early-Stage Implementation in LMIC (CATALYTIC) tool, which integrates contextual factors into the assessment of feasibility. Methods: The tool's items were developed through a systematic review and key informant interviews, and were later assessed for relevance and importance by 13 LMIC researchers and implementers employing a Delphi technique. The survey was then tested for usability by five individuals with CVD experience in LMIC. The CATALYTIC tool consists of 17 items that measure contextual factors that directly influence early-stage LMIC implementation. Descriptive analysis, logistic regression, item reliability using Cronbach's alpha, and exploratory factor analysis (EFA) were performed on survey data. Results: In a survey of 216 respondents from 46 countries, 63.4 to 81.5% of respondents noted a significant impact of contextual factors on implementation feasibility, with high reliability (Cronbach's alpha 0.88) for 12 items. The majority of interventions focused on patient-level care in rural settings. The survey items align primarily with constructs related to implementation climate and readiness for implementation, as well as inductive themes addressing existing needs and barriers to inform intervention design. The survey found diversity in geographic and experiential backgrounds, with significant representation from South Africa, Mexico, and India. Over a third identified as researchers, and 15% held multiple roles. The survey identified three distinct factors influencing how researchers and implementers assess CVD intervention feasibility in LMIC. A 6% increase in odds for moderately feasible interventions was linked to each point increase in the composite score of perceived contextual influence. Conclusion: Overall, the CATALYTIC tool with 12 reliable survey items can help researchers and implementers elucidate perceptions of contextual factors influencing the feasibility of CVD-related EBI in LMIC. The survey items reflect respondents' practical focus in resource-limited settings and can inform intervention design by addressing existing needs and barriers. The tool's integration of contextual factors into the assessment of feasibility can help overcome the inadequacy of existing instruments by providing more tailored and conceptually clear assessments of feasibility.

Indexed as

Cardiovascular DiseasesDeveloping CountriesEvidence-Based PracticeAdultFeasibility StudiesFemaleHumansMaleReproducibility of ResultsSurveys and Questionnairescardiovascular diseaseCATALYTIC toolcontextimplementation feasibilitylow- and middle-income countriesmeasurement and evaluationtool development

Identifiers

PMID41450503
PMCPMC12727921

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.